



Colin Bond

Colin Bond has extensive international experience in the CDMO and biopharma industries. Most recently, Colin served as the Chief Financial Officer of Sandoz, listed on the SIX Swiss Exchange, where Colin played a pivotal role in the successful spin-off from Novartis. Before joining Sandoz, Colin was the Chief Financial Officer at Vifor Pharma and Evotec. Additionally, Colin chaired the Audit Committee for Siegfried AG, a leading CDMO on the SIX Swiss Exchange, for ten years until May 2023. Currently, Colin is the Chair of the Audit Committee of BioPharma Credit PLC on the London Stock Exchange and a member of the Supervisory Board of Formycon AG. Colin also serves as a Non-Executive Director of Agomab Therapeutics NV and Oxford Biomedica PLC.

Earlier in Colin's career, Colin worked as a pharmacist, auditor, and management consultant for Procter & Gamble, Arthur Andersen, and PwC. Colin is a Fellow of the Institute of Chartered Accountants in England and Wales and a Member of the Royal Pharmaceutical Society of Great Britain. Colin holds a BSc in Pharmacy from Aston University and an MBA from London Business School.